• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝素酶与巨噬细胞在肝纤维化发病中的相互作用。

Heparanase and macrophage interplay in the onset of liver fibrosis.

机构信息

University of Padova, Dept. Biomedical Sciences, 35121, Padova, Italy.

University of Padova, Dept. of Surgery, Oncology and Gastroenterology, 35124, Padova, Italy.

出版信息

Sci Rep. 2017 Nov 2;7(1):14956. doi: 10.1038/s41598-017-14946-0.

DOI:10.1038/s41598-017-14946-0
PMID:29097791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5668295/
Abstract

The heparan sulfate endoglycosidase heparanase (HPSE) is involved in tumor growth, chronic inflammation and fibrosis. Since a role for HPSE in chronic liver disease has not been demonstrated to date, the current study was aimed at investigating the involvement of HPSE in the pathogenesis of chronic liver injury. Herein, we revealed that HPSE expression increased in mouse livers after carbon tetrachloride (CCl)-mediated chronic induction of fibrosis, but with a trend to decline during progression of the disease. In mouse fibrotic liver tissues HPSE immunostaining was restricted in necro-inflammatory areas, co-localizing with F4/80 macrophage marker and TNF-α. TNF-α treatment induced HPSE expression as well as HPSE secretion in U937 macrophages. Moreover, macrophage-secreted HPSE regulated the expression of α-SMA and fibronectin in hepatic stellate LX-2 cells. Finally, HPSE activity increased in the plasma of patients with liver fibrosis but it inversely correlated with liver stiffness. Our results suggest the involvement of HPSE in early phases of reaction to liver damage and inflammatory macrophages as an important source of HPSE. HPSE seems to play a key role in the macrophage-mediated activation of hepatic stellate cells (HSCs), thus suggesting that HPSE targeting could be a new therapeutic option in the treatment of liver fibrosis.

摘要

硫酸乙酰肝素内切糖苷酶(HPSE)参与肿瘤生长、慢性炎症和纤维化。由于迄今为止尚未证明 HPSE 在慢性肝病中的作用,本研究旨在研究 HPSE 在慢性肝损伤发病机制中的作用。本研究揭示,四氯化碳(CCl)介导的慢性纤维化诱导后,HPSE 在小鼠肝脏中的表达增加,但在疾病进展过程中呈下降趋势。在小鼠纤维化肝组织中,HPSE 免疫染色局限于坏死性炎症区域,与 F4/80 巨噬细胞标志物和 TNF-α共定位。TNF-α 处理诱导 U937 巨噬细胞中 HPSE 的表达和分泌。此外,巨噬细胞分泌的 HPSE 调节肝星状细胞 LX-2 中 α-SMA 和纤维连接蛋白的表达。最后,肝纤维化患者的血浆中 HPSE 活性增加,但与肝硬度呈负相关。我们的结果表明 HPSE 参与了对肝损伤和炎症性巨噬细胞的早期反应,是 HPSE 的重要来源。HPSE 似乎在巨噬细胞介导的肝星状细胞(HSCs)激活中起关键作用,因此表明 HPSE 靶向可能是治疗肝纤维化的新治疗选择。

相似文献

1
Heparanase and macrophage interplay in the onset of liver fibrosis.肝素酶与巨噬细胞在肝纤维化发病中的相互作用。
Sci Rep. 2017 Nov 2;7(1):14956. doi: 10.1038/s41598-017-14946-0.
2
Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells.细胞特异性过氧化物酶体增殖物激活受体 γ 缺失赋予非实质细胞中该核受体抗炎和抗纤维化特性。
J Hepatol. 2013 Nov;59(5):1045-53. doi: 10.1016/j.jhep.2013.06.023. Epub 2013 Jul 2.
3
Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis.使用负载 JQ1 和阿托伐他汀的壳聚糖纳米粒预防肝星状细胞活化——肝纤维化治疗的一种有前途的方法。
Eur J Pharm Biopharm. 2019 Jan;134:96-106. doi: 10.1016/j.ejpb.2018.11.018. Epub 2018 Nov 22.
4
C-C motif chemokine receptor 9 positive macrophages activate hepatic stellate cells and promote liver fibrosis in mice.C-C 基序趋化因子受体 9 阳性巨噬细胞激活肝星状细胞并促进小鼠肝纤维化。
Hepatology. 2013 Jul;58(1):337-50. doi: 10.1002/hep.26351. Epub 2013 May 31.
5
Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice.M1 极化巨噬细胞细胞疗法通过调节小鼠免疫微环境改善肝纤维化。
J Hepatol. 2017 Oct;67(4):770-779. doi: 10.1016/j.jhep.2017.05.022. Epub 2017 Jul 26.
6
Activation of Slit2-Robo1 signaling promotes liver fibrosis.Slit2-Robo1 信号的激活促进肝纤维化。
J Hepatol. 2015 Dec;63(6):1413-20. doi: 10.1016/j.jhep.2015.07.033. Epub 2015 Aug 8.
7
Mesenchymal stem cells and their secreted molecules predominantly ameliorate fulminant hepatic failure and chronic liver fibrosis in mice respectively.间充质干细胞及其分泌分子分别主要改善小鼠暴发性肝衰竭和慢性肝纤维化。
J Transl Med. 2016 Feb 9;14:45. doi: 10.1186/s12967-016-0792-1.
8
LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.脂多糖诱导的肿瘤坏死因子-α因子介导非酒精性脂肪性肝病中的促炎和促纤维化模式。
Oncotarget. 2015 Dec 8;6(39):41434-52. doi: 10.18632/oncotarget.5163.
9
Cav-1 deficiency promotes liver fibrosis in carbon tetrachloride (CCl)-induced mice by regulation of oxidative stress and inflammation responses.Cav-1 缺失通过调节氧化应激和炎症反应促进四氯化碳 (CCl) 诱导的小鼠肝纤维化。
Biomed Pharmacother. 2018 Jun;102:26-33. doi: 10.1016/j.biopha.2018.03.016. Epub 2018 Mar 14.
10
NLRC5 Deficiency Deregulates Hepatic Inflammatory Response but Does Not Aggravate Carbon Tetrachloride-Induced Liver Fibrosis.NLRC5 缺乏可使肝脏炎症反应失调,但不会加重四氯化碳诱导的肝纤维化。
Front Immunol. 2021 Oct 12;12:749646. doi: 10.3389/fimmu.2021.749646. eCollection 2021.

引用本文的文献

1
The Pathophysiological Functions of Heparanases: From Evolution, Structural and Tissue-Specific Perspectives.乙酰肝素酶的病理生理功能:从进化、结构和组织特异性角度探讨
FASEB J. 2025 Sep 15;39(17):e70976. doi: 10.1096/fj.202501859R.
2
Heparan sulfate chains in hepatocellular carcinoma.肝细胞癌中的硫酸乙酰肝素链
Gastroenterol Rep (Oxf). 2025 Mar 14;13:goaf023. doi: 10.1093/gastro/goaf023. eCollection 2025.
3
Macrophage Perspectives in Liver Diseases: Programmed Death, Related Biomarkers, and Targeted Therapy.巨噬细胞在肝脏疾病中的作用:程序性死亡、相关生物标志物和靶向治疗。

本文引用的文献

1
Heparanase: roles in cell survival, extracellular matrix remodelling and the development of kidney disease.乙酰肝素酶:在细胞存活、细胞外基质重塑和肾脏疾病发展中的作用。
Nat Rev Nephrol. 2017 Apr;13(4):201-212. doi: 10.1038/nrneph.2017.6. Epub 2017 Feb 6.
2
Heparanase: From basic research to therapeutic applications in cancer and inflammation.乙酰肝素酶:从基础研究到癌症与炎症治疗应用
Drug Resist Updat. 2016 Nov;29:54-75. doi: 10.1016/j.drup.2016.10.001. Epub 2016 Oct 6.
3
Heparanase is required for activation and function of macrophages.
Biomolecules. 2024 Jun 14;14(6):700. doi: 10.3390/biom14060700.
4
NLRP3 Inflammasome in Acute and Chronic Liver Diseases.急性和慢性肝病中的NLRP3炎性小体
Int J Mol Sci. 2024 Apr 20;25(8):4537. doi: 10.3390/ijms25084537.
5
Neonatal IL-4 Over-Exposure is Accompanied by Macrophage Accumulation in Dura Mater After Instant Anti-inflammatory Cytokine Response in CSF.新生儿白细胞介素-4过度暴露伴随着脑脊液中即时抗炎细胞因子反应后硬脑膜中巨噬细胞的积聚。
Cell Mol Neurobiol. 2024 Feb 5;44(1):18. doi: 10.1007/s10571-023-01451-4.
6
Sex Drives Functional Changes in the Progression and Regression of Liver Fibrosis.性别会导致肝纤维化的进展和消退中的功能变化。
Int J Mol Sci. 2023 Nov 17;24(22):16452. doi: 10.3390/ijms242216452.
7
Colorectal Cancer Cell Invasion and Functional Properties Depend on Peri-Tumoral Extracellular Matrix.结直肠癌细胞的侵袭和功能特性取决于肿瘤周围的细胞外基质。
Biomedicines. 2023 Jun 22;11(7):1788. doi: 10.3390/biomedicines11071788.
8
Role of heparanase in ARDS through autophagy and exosome pathway (review).乙酰肝素酶通过自噬和外泌体途径在急性呼吸窘迫综合征中的作用(综述)
Front Pharmacol. 2023 Jun 8;14:1200782. doi: 10.3389/fphar.2023.1200782. eCollection 2023.
9
Discovery and development of small-molecule heparanase inhibitors.小分子乙酰肝素酶抑制剂的发现与研制。
Bioorg Med Chem. 2023 Jul 15;90:117335. doi: 10.1016/j.bmc.2023.117335. Epub 2023 May 19.
10
Substrate Type and Concentration Differently Affect Colon Cancer Cells Ultrastructural Morphology, EMT Markers, and Matrix Degrading Enzymes.基质类型和浓度对结肠癌细胞超微结构形态、上皮间质转化标志物和基质降解酶的影响不同。
Biomolecules. 2022 Nov 30;12(12):1786. doi: 10.3390/biom12121786.
硫酸乙酰肝素酶是巨噬细胞激活和发挥功能所必需的。
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7808-E7817. doi: 10.1073/pnas.1611380113. Epub 2016 Nov 14.
4
Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.乙酰肝素酶对癌症、自噬和炎症的调控:治疗的新机制与靶点
FEBS J. 2017 Jan;284(1):42-55. doi: 10.1111/febs.13932. Epub 2016 Nov 16.
5
Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases.乙酰肝素酶:一种与包括罕见病在内的多种病症相关的多元药理学靶点。
Future Med Chem. 2016 Apr;8(6):647-80. doi: 10.4155/fmc-2016-0012. Epub 2016 Apr 8.
6
Recent data concerning heparanase: focus on fibrosis, inflammation and cancer.关于乙酰肝素酶的最新数据:聚焦纤维化、炎症和癌症。
Biomol Concepts. 2015 Dec;6(5-6):415-21. doi: 10.1515/bmc-2015-0021.
7
Impact of heparanase on renal fibrosis.乙酰肝素酶对肾纤维化的影响。
J Transl Med. 2015 Jun 4;13:181. doi: 10.1186/s12967-015-0538-5.
8
ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation.炎症性肠病中的细胞外基质重塑:无辜旁观者还是共犯?细胞外分子事件在维持肠道炎症中的新作用。
Gut. 2015 Mar;64(3):367-72. doi: 10.1136/gutjnl-2014-308048. Epub 2014 Nov 21.
9
Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4.由乙酰肝素酶产生的可溶性硫酸乙酰肝素片段通过Toll样受体4(TLR-4)触发促炎细胞因子的释放。
PLoS One. 2014 Oct 8;9(10):e109596. doi: 10.1371/journal.pone.0109596. eCollection 2014.
10
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence.辅助性硫酸乙酰肝素酶抑制剂PI-88治疗肝细胞癌复发
World J Gastroenterol. 2014 Aug 28;20(32):11384-93. doi: 10.3748/wjg.v20.i32.11384.